Analysts expect that ArQule, Inc. (NASDAQ:ARQL) will announce earnings of ($0.12) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for ArQule’s earnings. ArQule reported earnings per share of ($0.08) during the same quarter last year, which suggests a negative year over year growth rate of 50%. The company is expected to issue its next earnings results on Monday, November 6th.

According to Zacks, analysts expect that ArQule will report full year earnings of ($0.44) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.40) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover ArQule.

ArQule (NASDAQ:ARQL) last issued its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. ArQule had a negative net margin of 482.44% and a negative return on equity of 135.68%. During the same quarter last year, the firm earned ($0.07) earnings per share.

Several research analysts have weighed in on ARQL shares. ValuEngine downgraded ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded ArQule from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Friday, September 8th.

A hedge fund recently raised its stake in ArQule stock. First Eagle Investment Management LLC grew its position in shares of ArQule, Inc. (NASDAQ:ARQL) by 8.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 11,847,575 shares of the biotechnology company’s stock after acquiring an additional 934,842 shares during the quarter. First Eagle Investment Management LLC owned about 16.65% of ArQule worth $14,691,000 at the end of the most recent reporting period. Institutional investors own 60.95% of the company’s stock.

WARNING: “ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.12 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at

Shares of ArQule (ARQL) traded down 0.84% during trading on Monday, reaching $1.18. 199,636 shares of the company’s stock were exchanged. The firm’s market cap is $83.98 million. ArQule has a 12 month low of $0.92 and a 12 month high of $1.82. The stock has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.13.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with's FREE daily email newsletter.